Tempo Therapeutics
A regenerative-medicine company developing injectable microporous scaffolds that help the body rebuild tissue at damaged sites.
$14.5MFunding
ParticipantYB
YK Bioventures
Activity from announced rounds
Activity in this selectionUnited States · Oct 9, 2026 · Jan 1, 2026
YK Bioventures is the life-sciences venture firm whose own profile identifies Think Bio, Vivere, Moonwalk and Tempo.
Recorded funding activity
Think develops small-molecule medicines. Moonwalk targets fat-tissue pathways, while Tempo develops regenerative scaffolds. These programs pursue distinct therapeutic mechanisms within the recorded activity.
Sources
- Rounds participated in
- 4
- Confirmed lead rounds
- 1 2 roles undisclosed
- New companies
- 4 First participation on record · 0 follow-on
- Funding in participating rounds
- $149.5M 4 disclosed · full round size, not this investor’s share
By stage
By primary sector
By country
Rounds
4 in this selectionMoonwalk Biosciences
Moonwalk Biosciences is developing adipose-targeted siRNA medicines for obesity and cardiometabolic disease. Its lead programs are designed to alter fat-tissue pathways while limiting effects on other tissues, with the lead obesity candidate in IND-enabling development ahead of planned human testing in 2027.
$70MSeries B
LeadThink Bioscience
Develops small molecule drugs for historically challenging drug targets
$55MSeries A
Role not disclosedVivere Oncotherapies
Vivere Oncotherapies develops cancer treatments designed to activate immune recognition and destruction of cancer cells.
$10MSeries A
Role not disclosed